These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 34515975)

  • 1. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.
    Carr WW; Jain N; Sublett JW
    Adv Ther; 2021 Oct; 38(10):5046-5064. PubMed ID: 34515975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A.
    Kerscher M; Wanitphakdeedecha R; Trindade de Almeida A; Maas C; Frevert J
    J Drugs Dermatol; 2019 Jan; 18(1):52-57. PubMed ID: 30681794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.
    Martin MU; Frevert J; Tay CM
    Toxins (Basel); 2024 Feb; 16(2):. PubMed ID: 38393178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
    Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
    mSphere; 2016; 1(1):. PubMed ID: 27303710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence on botulinum toxin in selected disorders.
    Zakin E; Simpson D
    Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile.
    Dashtipour K; Pedouim F
    Semin Neurol; 2016 Feb; 36(1):29-33. PubMed ID: 26866493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Native and Engineered Botulinum Neurotoxins.
    Steward L; Brin MF; Brideau-Andersen A
    Handb Exp Pharmacol; 2021; 263():63-89. PubMed ID: 32274579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
    Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
    Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical differences between botulinum neurotoxin type A and B.
    Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
    Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D.
    Garcia-Rodriguez C; Yan S; Geren IN; Knopp KA; Dong J; Sun Z; Lou J; Conrad F; Wen WH; Farr-Jones S; Smith TJ; Brown JL; Skerry JC; Smith LA; Marks JD
    Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.